Nothing Special   »   [go: up one dir, main page]

CO2021009025A2 - Proteínas de unión multiespecíficas basadas en pseudofab - Google Patents

Proteínas de unión multiespecíficas basadas en pseudofab

Info

Publication number
CO2021009025A2
CO2021009025A2 CONC2021/0009025A CO2021009025A CO2021009025A2 CO 2021009025 A2 CO2021009025 A2 CO 2021009025A2 CO 2021009025 A CO2021009025 A CO 2021009025A CO 2021009025 A2 CO2021009025 A2 CO 2021009025A2
Authority
CO
Colombia
Prior art keywords
binding proteins
pseudofab
multispecific binding
domain
multispecific
Prior art date
Application number
CONC2021/0009025A
Other languages
English (en)
Inventor
Thomas Langer
Christian Lange
Ercole Rao
Wulf Dirk Leuschner
Christian Beil
Gerhard Hessler
Sandra Weil
Soraya Hoelper
Karl-Christian Engel
Cendrine Lemoine
Bruederle Sevim Oezguer
Nadja Spindler
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP18306840.2A external-priority patent/EP3674319A1/en
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of CO2021009025A2 publication Critical patent/CO2021009025A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Se proporcionan proteínas de unión que comprenden un dominio pseudoFab que incluye un dominio inactivado estabilizado y un segundo VH/VL que forman un primer dominio de unión a antígeno funcional. También se proporcionan proteínas de unión multiespecíficas que comprenden al menos un pseudoFab. También se proporcionan proteínas de unión multiespecíficas, ácidos nucleicos que codifican proteínas de unión y proteínas de unión multiespecíficas, vectores de expresión, células anfitrionas, una composición farmacéutica y métodos de tratamiento administrando las proteínas de unión o proteínas de unión multiespecíficas descritas en la presente memoria.
CONC2021/0009025A 2018-12-24 2021-07-09 Proteínas de unión multiespecíficas basadas en pseudofab CO2021009025A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306840.2A EP3674319A1 (en) 2018-12-24 2018-12-24 Pseudofab-based multispecific binding proteins
EP19305813 2019-06-21
PCT/IB2019/061304 WO2020136564A1 (en) 2018-12-24 2019-12-23 Pseudofab-based multispecific binding proteins

Publications (1)

Publication Number Publication Date
CO2021009025A2 true CO2021009025A2 (es) 2021-12-10

Family

ID=69174547

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0009025A CO2021009025A2 (es) 2018-12-24 2021-07-09 Proteínas de unión multiespecíficas basadas en pseudofab

Country Status (16)

Country Link
US (2) US11739160B2 (es)
EP (1) EP3902825A1 (es)
JP (1) JP2024504880A (es)
KR (1) KR20220015369A (es)
CN (1) CN114885609A (es)
AU (1) AU2019416895A1 (es)
BR (1) BR112021012337A2 (es)
CA (1) CA3124770A1 (es)
CO (1) CO2021009025A2 (es)
IL (1) IL284317A (es)
MA (1) MA54601A (es)
MX (1) MX2021007677A (es)
PH (1) PH12021500028A1 (es)
SG (1) SG11202106393SA (es)
TW (1) TW202041534A (es)
WO (1) WO2020136564A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12021500028A1 (en) 2018-12-24 2022-05-02 Sanofi Sa Pseudofab-based multispecific binding proteins
US11613576B2 (en) * 2019-04-09 2023-03-28 Sanofi Trispecific binding proteins, methods, and uses thereof
WO2024206669A2 (en) * 2023-03-29 2024-10-03 Virtuoso Binco, Inc. Antibodies for targeting cd47 and b7h3 and methods of use thereof

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4118120A1 (de) 1991-06-03 1992-12-10 Behringwerke Ag Tetravalente bispezifische rezeptoren, ihre herstellung und verwendung
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5732168A (en) 1995-10-31 1998-03-24 Hewlett Packard Company Thermal optical switches for light
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
US20040220388A1 (en) 2000-06-30 2004-11-04 Nico Mertens Novel heterodimeric fusion proteins
US6833441B2 (en) 2001-08-01 2004-12-21 Abmaxis, Inc. Compositions and methods for generating chimeric heteromultimers
US8420783B2 (en) 2004-12-08 2013-04-16 Immunomedics, Inc. Method and compositions for immunotherapy of inflammatory and immune-dysregulatory diseases
NZ612578A (en) 2005-08-19 2014-11-28 Abbvie Inc Dual variable domain immunoglobin and uses thereof
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
PL1999154T3 (pl) 2006-03-24 2013-03-29 Merck Patent Gmbh Skonstruowane metodami inżynierii heterodimeryczne domeny białkowe
WO2007114325A1 (ja) 2006-03-31 2007-10-11 Chugai Seiyaku Kabushiki Kaisha 二重特異性抗体を精製するための抗体改変方法
AT503889B1 (de) 2006-07-05 2011-12-15 Star Biotechnologische Forschungs Und Entwicklungsges M B H F Multivalente immunglobuline
SI2235064T1 (sl) 2008-01-07 2016-04-29 Amgen Inc. Metoda za izdelavo heterodimernih molekul - protitelesa fc z uporabo elektrostatičnih usmerjevalnih učinkov
EP2382234A2 (en) 2008-12-23 2011-11-02 Genentech, Inc. Immunoglobulin variants with altered binding to protein a
US9067986B2 (en) 2009-04-27 2015-06-30 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
US8703132B2 (en) * 2009-06-18 2014-04-22 Hoffmann-La Roche, Inc. Bispecific, tetravalent antigen binding proteins
WO2010151792A1 (en) 2009-06-26 2010-12-29 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
EP2522724B1 (en) 2009-12-25 2020-02-05 Chugai Seiyaku Kabushiki Kaisha Polypeptide modification method for purifying polypeptide multimers
WO2011117653A1 (en) * 2010-03-25 2011-09-29 Ucb Pharma S.A. Disulfide stabilized dvd-lg molecules
CA2796181C (en) 2010-04-20 2023-01-03 Genmab A/S Heterodimeric antibody fc-containing proteins and methods for production thereof
EP2569337A1 (en) 2010-05-14 2013-03-20 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
PL2606064T3 (pl) 2010-08-16 2015-07-31 Novimmune Sa Sposoby wytwarzania wieloswoistych i wielowartościowych przeciwciał
EP2635607B1 (en) 2010-11-05 2019-09-04 Zymeworks Inc. Stable heterodimeric antibody design with mutations in the fc domain
TWI803876B (zh) 2011-03-28 2023-06-01 法商賽諾菲公司 具有交叉結合區定向之雙重可變區類抗體結合蛋白
AU2012351751B2 (en) 2011-10-19 2017-09-07 Novimmune S.A. Methods of purifying antibodies
SI2794905T1 (sl) 2011-12-20 2020-08-31 Medimmune, Llc Modificirani polipeptidi za ogrodja bispecifičnega protitelesa
AU2013234039B2 (en) 2012-03-13 2018-02-01 Novimmune S.A. Readily isolated bispecific antibodies with native immunoglobulin format
WO2014004586A1 (en) 2012-06-25 2014-01-03 Zymeworks Inc. Process and methods for efficient manufacturing of highly pure asymmetric antibodies in mammalian cells
WO2014049003A1 (en) 2012-09-25 2014-04-03 Glenmark Pharmaceuticals S.A. Purification of hetero-dimeric immunoglobulins
EP2938636A2 (en) 2012-12-28 2015-11-04 AbbVie Inc. High-throughput system and method for identifying antibodies having specific antigen binding activities
US9879081B2 (en) 2013-06-25 2018-01-30 Samsung Electronics Co., Ltd. Protein complex, bispecific antibody including the protein complex, and method of preparation thereof
US11261262B2 (en) 2013-09-03 2022-03-01 Novimmune Sa Readily isolated bispecific binding molecules with native format having mutated constant regions
US10160812B2 (en) * 2014-04-11 2018-12-25 Medimmune, Llc Bispecific HER2 antibodies
JP6868394B2 (ja) * 2014-05-16 2021-05-12 ファイザー・インク 二重特異性抗体
US20170210818A1 (en) 2014-06-06 2017-07-27 The California Institute For Biomedical Research Constant region antibody fusion proteins and compositions thereof
AR101262A1 (es) 2014-07-26 2016-12-07 Regeneron Pharma Plataforma de purificación para anticuerpos biespecíficos
GB201414823D0 (en) 2014-08-20 2014-10-01 Argen X Bv Multispecific antibodies
CN107001482B (zh) * 2014-12-03 2021-06-15 豪夫迈·罗氏有限公司 多特异性抗体
US10457749B2 (en) 2015-03-13 2019-10-29 Novimmune Sa Methods of purifying bispecific antibodies
US20180201693A1 (en) 2015-07-09 2018-07-19 Genmab A/S Bispecific and multispecific antibodies and method for isolation of such
CN109476732B (zh) 2016-04-13 2024-03-22 赛诺菲 三特异性和/或三价结合蛋白
EP3684805A4 (en) * 2017-09-22 2021-06-09 Wuxi Biologics Ireland Limited. NEW BISPECIFIC POLYPEPTIDIC COMPLEXES
EP3674319A1 (en) 2018-12-24 2020-07-01 Sanofi Pseudofab-based multispecific binding proteins
PH12021500028A1 (en) 2018-12-24 2022-05-02 Sanofi Sa Pseudofab-based multispecific binding proteins
US20230103563A1 (en) * 2020-03-30 2023-04-06 Sanofi Split ch2 domains
EP4303231A1 (en) * 2021-02-07 2024-01-10 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Bispecific antibody

Also Published As

Publication number Publication date
AU2019416895A2 (en) 2021-09-09
PH12021500028A1 (en) 2022-05-02
KR20220015369A (ko) 2022-02-08
AU2019416895A1 (en) 2021-08-12
WO2020136564A1 (en) 2020-07-02
MA54601A (fr) 2022-03-30
IL284317A (en) 2021-08-31
EP3902825A1 (en) 2021-11-03
US20230391888A1 (en) 2023-12-07
BR112021012337A2 (pt) 2021-09-14
CN114885609A (zh) 2022-08-09
JP2024504880A (ja) 2024-02-02
SG11202106393SA (en) 2021-07-29
MX2021007677A (es) 2021-12-10
CA3124770A1 (en) 2020-07-02
TW202041534A (zh) 2020-11-16
US11739160B2 (en) 2023-08-29
US20200255540A1 (en) 2020-08-13

Similar Documents

Publication Publication Date Title
CO2021009025A2 (es) Proteínas de unión multiespecíficas basadas en pseudofab
BR112018074463A2 (pt) anticorpos anti-tim-3 e métodos de uso dos mesmos.
BR112019004998A2 (pt) anticorpos anti-pd-1(cd279)
BR112018076260A2 (pt) anticorpo ou fragmento do mesmo que se liga especificamente a hpd-l1, anticorpo biespecífico ou proteína de fusão, uso de um anticorpo ou fragmento, método, composição farmacêutica, método de modulação, método de inibição, método de tratamento, ácido nucleico, vetor, hospedeiro e imunocitocina
BR112017025564A2 (pt) anticorpos anti-ctla-4 e métodos de uso dos mesmos
PE20181805A1 (es) Composiciones y anticuerpos anti-tim-3
BR112018003186A2 (pt) anticorpos anti-pd-1 e seus métodos de uso
EA201792573A1 (ru) Триспецифические связанные белки и способы их применения
CY1123274T1 (el) Αντισωματα εναντι-οχ40 και χρησεις αυτων
BR112017008165B8 (pt) anticorpo de domínio único direcionado contra um componente intracelular e seu uso, métodos in vitro para medir os níveis do referido anticorpo e para diagnosticar um distúrbio mediado por um componente intracelular, polipeptídeo isolado e composição compreendendo o referido anticorpo ou polipeptídeo isolado
BR112018073761A2 (pt) proteínas de ligação ao cd3 de fragmento variável de cadeia única
BR112019005726A8 (pt) Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga ao cd27 humano, polipeptídeo isolado, ácido nucleico isolado, vetor de expressão, célula hospedeira, composição, métodos de produção de um anticorpo ou de um fragmento de ligação ao antígeno, de tratamento de câncer e de tratamento de uma infecção ou de uma doença infecciosa, e, uso do anticorpo ou do fragmento de ligação ao antígeno
BR112019000970A2 (pt) proteínas de ligação ao antígeno multiespecíficas e métodos de uso das mesmas
EA201890736A1 (ru) Модуляторы корового белка вируса гепатита b
EA201990598A1 (ru) Высококонцентрированные низковязкие препараты ингибирующего masp-2 антитела, наборы и способы
BR112018003665A2 (pt) métodos e composições para vetores virais de evasão de anticorpo
PE20170665A1 (es) Anticuerpos anti-tau humanizados
BR112018074468A2 (pt) anticorpos anti-cd40 e suas utilizações
BR112019001737A2 (pt) expressão de pten-long com vírus oncolíticos
BR112016022814A8 (pt) composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico
CO2021008995A2 (es) Proteínas de unión multiespecíficas con dominios fab mutantes
BR112017009790A2 (pt) anticorpos direcionados ao anti-ang2 e métodos de uso
BR112017006598A2 (pt) anticorpo de repetições antidipeptídeo derivado de ser humano (dprs)
MX2020011027A (es) Constructos de anticuerpos biespecíficos trivalentes.
BR112022003740A2 (pt) Anticorpos anti-cd96 e métodos de uso dos mesmos